Advances in Cancer Therapy: A Comprehensive Review of Fourth Generation EGFR Inhibitors and their Role in Defeating Drug Resistance

The treatment of cancer has changed significantly as a result of the development of targeted medications, particularly inhibitors of the receptor for epidermal growth factor (EGFR), which is crucial for the development and survival of cancer. Cancers of the colorectal, head and neck, and non-small cell lung varieties often include EGFR overexpression and mutations. The safety records, clinical effectiveness, and action mechanisms of 4 thgeneration EGFR inhibitors are the primary foci of this review. The T790M mutation is one example of a resistance mechanism that these newer, more potent inhibitors aim to counteract. In order to give patients with EGFR-mutant cancers that are resistant to earlier treatments new hope, the review outlines recent clinical developments and examines the potential applications of 4 th -generation EGFR inhibitors in cancer treatment.